Peri Marta, Fazio Nicola
Medical Oncology, Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Italy.
Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milan, Italy.
Lung Cancer (Auckl). 2020 Jul 8;11:41-52. doi: 10.2147/LCTT.S249928. eCollection 2020.
Neuroendocrine tumors (NETs) of the lung are well-differentiated neuroendocrine neoplasms (NENs) with a heterogeneous clinical behaviour. Unlike gastroenteropancreatic NENs where therapeutic armamentarium clearly increased over the last decade, everolimus represented the only clinical practical innovation for lung NET patients over the last years. Therefore, for lung NETs, a multidisciplinary discussion within a dedicated team remains critical for an adequate decision-making. Although the main regulatory authorities considered the everolimus-related evidence is enough to approve the drug in advanced lung NETs, several clinical features deserve to be discussed. In this review, we systemically and critically analysed the main clinical studies including patients with advanced lung NETs receiving everolimus. Furthermore, we reported the biological and clinical background of everolimus in lung NET setting. The purpose of this review is to help clinical community to contextualize evidence and experience for a personalised use of this drug in clinical practice in the context of advanced lung NET patients.
肺神经内分泌肿瘤（NETs）是具有异质性临床行为的高分化神经内分泌肿瘤（NENs）。与胃肠胰神经内分泌肿瘤不同，在过去十年中胃肠胰神经内分泌肿瘤的治疗手段明显增多，而依维莫司是过去几年中肺神经内分泌肿瘤患者唯一具有临床实用性的创新药物。因此，对于肺神经内分泌肿瘤而言，在一个专门的团队内进行多学科讨论对于做出恰当决策仍然至关重要。尽管主要监管机构认为与依维莫司相关的证据足以批准该药物用于晚期肺神经内分泌肿瘤，但仍有几个临床特征值得探讨。在本综述中，我们系统且批判性地分析了主要临床研究，这些研究纳入了接受依维莫司治疗的晚期肺神经内分泌肿瘤患者。此外，我们报告了依维莫司在肺神经内分泌肿瘤背景下的生物学和临床背景。本综述的目的是帮助临床界将证据和经验置于特定情境中，以便在晚期肺神经内分泌肿瘤患者的临床实践中个性化使用该药物。
